Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Risperidone 2 mg Clear all
Completed Phase 4 Interventional

Improving Work Outcome in People With Recent-onset Schizophrenia

NCT00203788
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support, Workplace Fundamentals Module, Brokered Vocational Rehabilitation, Oral risperidone, Skills training group
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

NCT01207414
View directory record Official record
Conditions
Schizophrenia
Interventions
iloperidone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 64 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
59
States / cities
Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 6:40 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCT00337662
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Results available

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

NCT02203838
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 6:40 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

NCT00571688
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal (risperidone) Consta, Treatment as usual
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

NCT00722176
View directory record Official record
Conditions
Schizophrenia
Interventions
BL-1020, BL-1020 10-30 mg, risperidone
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Results available

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

NCT01333072
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 28, 2026, 6:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Risperidone or Aripiprazole (patients only)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 28, 2026, 6:40 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 28, 2026, 6:40 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCT07565428
View directory record Official record
Conditions
Negative Symptoms of Schizophrenia
Interventions
Roluperidone, risperidone, aripiprazole, olanzapine, Placebo
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Bellflower, California • Culver City, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Vabicaserin in Subjects With Schizophrenia

NCT00563706
View directory record Official record
Conditions
Schizophrenia
Interventions
vabicaserin, risperidone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

NCT01376076
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Risperidone/Moxifloxacin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Willingboro, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

NCT02687984
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Garden Grove, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 28, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 28, 2026, 6:40 AM EDT